PLEGRIDY
Biological
Biogen, Inc.
Total Payments
$5.9M
Transactions
9,588
Doctors
1,099
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $64,457 | 446 | 212 |
| 2023 | $63,575 | 510 | 344 |
| 2022 | $384,335 | 930 | 333 |
| 2021 | $334,403 | 711 | 362 |
| 2020 | $486,772 | 242 | 127 |
| 2019 | $3.0M | 143 | 58 |
| 2018 | $982,253 | 2,418 | 31 |
| 2017 | $572,455 | 4,188 | 40 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.1M | 6,655 | 86.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $657,870 | 272 | 11.2% |
| Consulting Fee | $49,208 | 20 | 0.8% |
| Food and Beverage | $41,465 | 2,106 | 0.7% |
| Travel and Lodging | $22,855 | 74 | 0.4% |
| Education | $4,682 | 461 | 0.1% |
Payments by Type
Research
$5.1M
6,655 transactions
General
$776,080
2,933 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Open-label, Crossover Study to Evaluate the Bioequivalence of Intramuscular BIIB017 (Peginterferon Beta-1a) and Subcutaneous BIIB017 in Healthy Volunteers | Biogen, Inc. | $3.1M | 0 |
| Plegridy Observational Program | Biogen, Inc. | $1.3M | 0 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | Biogen, Inc. | $171,631 | 2 |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Biogen, Inc. | $145,857 | 1 |
| Plegridy (peginterferon 1a) Real World Effectiveness and Safety Observational Program | Biogen, Inc. | $110,114 | 0 |
| Plegridy Lactation Study | Biogen, Inc. | $87,958 | 0 |
| A cross-over trial of warm and cold compress to reduce injection site reactions due to peginterferon-beta-1a in multiple sclerosis. | Biogen, Inc. | $47,920 | 0 |
| IIT, 2714258, EvergreenHealth, Dr. Theodore Brown, US-MSG-14-10693, A cross over trial of warm and cold compress to reduce injection site reactions due to peginterferon-beta-1a in multiple sclerosis | Biogen, Inc. | $23,575 | 0 |
| Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects | Biogen, Inc. | $18,528 | 0 |
| Long-Term Safety and Efficacy Study of Peginterferon Beta-1a | Biogen, Inc. | $11,824 | 0 |
| A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis | Biogen, Inc. | $6,413 | 0 |
| Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO) | Biogen, Inc. | $1,875 | 1 |
| Plegridy (peginterferon 1a) Real World Effectiveness and Safety Observational Program | Biogen, Inc. | $1,055 | 0 |
| Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | Biogen, Inc. | $398.00 | 0 |
Top Doctors Receiving Payments for PLEGRIDY — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology | Fullerton, CA | $8,541 | 7 |
| , APRN, AGCNS-BC | Neuroscience | New Orleans, LA | $8,455 | 10 |
| , PA-C | Physician Assistant | Springfield, MA | $8,397 | 10 |
| , M.D | Neurology | Los Angeles, CA | $8,246 | 2 |
| , MD | Neurology | Sunrise, FL | $7,996 | 20 |
| , MD PHD | Neurology | Ann Arbor, MI | $7,965 | 5 |
| , DO | Neurology | Dublin, OH | $7,858 | 9 |
| , MD | Neurology | Beaver, PA | $7,607 | 5 |
| , MD | Neurology | Buffalo, NY | $7,346 | 16 |
| , D.O | Neurology | Baltimore, MD | $7,147 | 2 |
| , M.D | Neurology | Minneapolis, MN | $6,799 | 5 |
| , DO | Neurology | Orange, CA | $6,502 | 5 |
| , M.D | Neurology | Stanford, CA | $6,450 | 1 |
| , M.D | Specialist | Traverse City, MI | $6,325 | 6 |
| , M.D | Neurology | Omaha, NE | $6,294 | 6 |
| Richard Shubin | — | Arcadia, CA | $6,039 | 4 |
| Sunita Tummala | Neurology | Flint, MI | $5,959 | 8 |
| , MD | Neurology | Naples, FL | $5,535 | 12 |
| , MD | Neurology | Chicago, IL | $5,363 | 3 |
| , M.D | Neurology | Derby, CT | $5,250 | 2 |
| , DO | Neurology | Novi, MI | $5,109 | 9 |
| , MD | Vascular Neurology | Louisville, KY | $5,100 | 4 |
| , M.D | Neurological Surgery | Atlanta, GA | $5,049 | 3 |
| , MD | Neurology | San Francisco, CA | $4,951 | 2 |
| , NP | Adult Health | Amherst, NY | $4,934 | 30 |
Ad
Manufacturing Companies
- Biogen, Inc. $5.9M
Product Information
- Type Biological
- Total Payments $5.9M
- Total Doctors 1,099
- Transactions 9,588
About PLEGRIDY
PLEGRIDY is a biological associated with $5.9M in payments to 1,099 healthcare providers, recorded across 9,588 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..
Payment data is available from 2017 to 2024. In 2024, $64,457 was paid across 446 transactions to 212 doctors.
The most common payment nature for PLEGRIDY is "Unspecified" ($5.1M, 86.8% of total).
PLEGRIDY is associated with 14 research studies, including "A Phase 1, Open-label, Crossover Study to Evaluate the Bioequivalence of Intramuscular BIIB017 (Peginterferon Beta-1a) and Subcutaneous BIIB017 in Healthy Volunteers" ($3.1M).